Abcuro, Inc. is a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells.

Abcuro, Inc.

Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1).  The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies. IBM is a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. Abcuro has received FDA orphan drug designation for ABC008 in IBM. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.

Kaitai Capital

ShangPharma Innovation

Partners Innovation Fund

Hongsen Investment Group

Mass General Brigham Ventures

Samsara BioCapital

Sanofi Ventures

Pontifax

RA Capital Management

Eurofarma

BlackRock

Soleus Capital

Bain Capital Life Sciences

Redmile Group

Abcuro, Inc

#InclusionBodyMyositis is a debilitating autoimmune disease impacting up to 50,000 people in the U.S. and Europe. Abcuro is committed to developing a potential new treatment option for this #raredisease. Learn more here:  https://lnkd.in/ePXaHN3w

#ShowYourRare
#ShowYourStripes

We are excited to have Stephanie join the Abcuro team as our CMC project manager. 
#welcomeaboard

Joining us in welcoming Andrew to Abcuro!  We are excited to have him on board as our Director of Quality Control.
#welcometotheteam

Next week! We’re looking forward to Oppenheimer & Co. Inc.’s 34th Annual Healthcare Conference where our CEO, Alex Martin, will be presenting Abcuro’s science and our work in #InclusionBodyMyositis. 
  
#OPCOLifeSciences #biotech #autoimmune #oncology

Please join us in welcoming Chidi to Abcuro as our new director of analytical development. We're excited to have you as part of our team!

Please join us in welcoming Jeffrey to the Abcuro team!  We're excited to have you aboard.

We’re excited to welcome Mark Pruzanski, MA, MD as Chairman of our Board of Directors. Dr. Pruzanski is a life science veteran bringing over 30 years of experience in the industry and a proven track record of guiding new medicines through the clinic to patients in need. Learn more: https://lnkd.in/eh8qK4hh 

#biotech #leadership #autoimmune #InclusionBodyMyositis

We’re headed to London to join Jefferies for their Annual Healthcare Conference and will be hosting meetings on November 15th and 16th. If you’re attending and want to learn more about Abcuro, please reach out! 

#biotech #InclusionBodyMyositis
#autoimmune #oncology #JefferiesHealthcare

We’re looking forward to participating in the Stifel Healthcare Conference this week. If you’re interested in hearing more about our work in autoimmune diseases including #InclusionBodyMyositis, check out the presentation by CEO Alex Martin on Tuesday November 14th, 8am ET. 

#biotech #autoimmune #oncology

We are excited to announce that we have initiated Part B of our registrational Phase 2/3 MUSCLE study of ulviprubart (ABC008) for the treatment of #InclusionBodyMyositis. Learn more: https://lnkd.in/emDdhBgW

#biotech #autoimmune #clinicaltrials

COM:ABCURO

Abcuro, Inc.

People Not Available